Is Tirzepatide safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Tirzepatide. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
Five women who were receiving tirzepatide in doses of 2.5 to 5 mg per week. All mothers continued breastfeeding to varying extents, but none reported observed adverse effects in their infants attributable to tirzepatide.[ 1 ]
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. The manufacturer reports a study of 11 lactating women who were given a single 5 mg subcutaneous dose of tirzepatide. The concentration of tirzepatide in breastmilk was undetectable ( 4 mcg/L) in 164 of 171 milk samples. The cumulative amount of tirzepatide detected in the remaining 7 breastmilk samples over the 28-day sampling period was equivalent to less than 0.02% of the maternal administered dose, with the last measurable concentrations occurring 5 days after the dose. This study does not account for accumulation that would occur during typical use, so the amounts in milk at steady-state are probably greater than indicated. Five women who were receiving subcutaneous tirzepatide in doses of 2.5 to 5 mg per week collected milk samples multiple times on the day they received their drug dose, and one woman collected a sample 168 hours after her dose. A few samples found unquantifiable milk levels below the limit of detection of 0.7 mcg/L and no samples exceeded the limit of quantification of 2.38 mcg/L.[ 1 ] Infant Levels. Relevant published information was not found as of the revision date.
Alternatives LactMed lists
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.